PRESS RELEASE
MSI (‘Microsatellite Instability’) is the result of inactivation of the body’s so-called DNA mismatch repair (MMR) system. Consequently, errors that spontaneously occur during the normal process of DNA replication are no longer corrected, contributing to tumor growth and evolution. Approximately 15% of colorectal (CRC) patients and 4-5% of mCRC patients have MSI-High or mismatch repair deficient (dMMR) biomarkers3. In addition to prognostic applications for CRC, MSI is believed to be an independent factor that may predict a patient’s response to certain immunotherapies4. The fully automated and CE-marked IVD Idylla™ MSI Test provides information on the MSI status5,[6],[7] of CRC tumors within approximately 150 minutes from just one slice of FFPE8 tumor tissue, without the need of a reference sample.
Bristol-Myers Squibb’s Opdivo® (nivolumab) plus low-dose Yervoy®9 (ipilimumab) is the first immuno-oncology combination treatment approved by the
Biocartis’ joint venture Wondfo-Cartis11 will commercialize the Idylla™ MSI test in the People’s
Herman Verrelst, CEO of
----- END ----
More information:
Head of
e-mail rdegrave@biocartis.com
tel +32 15 631 729
mobile +32 471 53 60 64
About Biocartis
Forward-looking statements
Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company's or, as appropriate, the Company directors' or managements' current expectations and projections concerning future events such as the Company's results of operations, financial condition, liquidity, performance, prospects, growth, strategies and the industry in which the Company operates. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.
1 On
2 A companion diagnostic (CDx) test is a test used as a companion to a therapeutic drug, that helps predict if a patient is likely to respond to a treatment or not
3 Source: https://fightcolorectalcancer.org/fight/diagnosis/what-is-msi-and-mss/, last consulted on
4 Ongoing research to support the hypothesis that MSI can be an independent factor to help predict a patient’s response to certain immunotherapies, includes: Le et al. (2015) N-Eng-J-Med: 10.1056/NEJMoa1500596, showing that MMR status predicted clinical benefit of immune checkpoint blockade therapy; and Le et al. (2017) Science: 10.1126/science.aan6733, showing that MSI is associated with overall mutational and indel load of the tumor, neoantigen load, and lymphocyte infiltration of the tumor, and has been shown to be predictive for response to immunotherapies such as anti-PD-1 in a pan-cancer setting
5 Maertens et al. Annals of Oncology (2017) 28 (suppl_5): v22-v42
6
7
8 FFPE = formalin fixed, paraffin embedded
9 3 mg/kg Opdivo® plus 1 mg/kg Yervoy®. Approved in
10 Treatment with fluoropyrimidine, oxaliplatin and irinotecan
11 On
© OMX, source